Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 16/20 | 0.73 |
| ▸ | FADS1 | O60427 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573697 | 0.89 | GRM2 (0.82) | GRM2FADS1MAOAMAOB | |
| SCHEMBL14214167 | 0.89 | GRM2 (0.82) | GRM2FADS1MAOAMAOB | |
| SCHEMBL27915892 | 0.86 | GRM2 (0.66) | GRM2FADS1MAOAMAOB | |
| SCHEMBL1032517 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOB | |
| SCHEMBL30063909 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOB | |
| SCHEMBL3087781 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOB | |
| SCHEMBL1557298 | 0.86 | MAOA (0.71) | GRM2FADS1MAOAMAOB | |
| SCHEMBL6233611 | 0.86 | GRM2 (0.66) | GRM2FADS1MAOAMAOB | |
| SCHEMBL2896939 | 0.86 | GRM2 (0.66) | GRM2FADS1MAOAMAOB | |
| SCHEMBL14183165 | 0.85 | GRM2 (0.65) | GRM2FADS1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | MELINTA SUBSIDIARY CORP. | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | PCNA, PGC, SBDS | GRM2 3664/4885FADS1 1565/4885MAOA 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.